Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial

Table 2 IPTW-adjusted univariate and multivariate analyses of the relationship between PFS and clinical factors in TH group

Factor	Univariate analysis			Multivariate analysis
Factor	HR	95%CI	P value	HR	95%CI	P value
Age, years (≥ 55 vs. < 55)	1.030	0.74–1.45	0.853	0.980	0.69–1.39	0.905
Disease type at screening (visceral vs. nonvisceral)	1.440	1.10–1.88	0.008	1.420	1.08–1.86	0.011
ECOG performance status (≥ 1 vs. 0)	1.290	1.02–1.65	0.037	1.260	0.98–1.61	0.074
Hormone-receptor status
Negative vs. positive	1.070	0.85–1.36	0.553	1.130	0.89–1.44	0.320
Unknown vs. positive	1.310	0.92–1.87	0.136	1.440	1.07–1.93	0.016
Previous neoadjuvant or adjuvant systemic therapy (YES vs. no)	1.020	0.81–1.29	0.854	1.010	0.79–1.28	0.956
NLR (High vs. low)	1.350	1.07–1.70	0.012	1.380	1.09–1.74	0.007

Bold indicates P < 0.05
HR Hazard ratio, 95% CI 95% Confidence interval, NLR Neutrophil to lymphocyte ratio, IPTW Inverse probability of treatment weighting, TH group Trastuzumab plus docetaxel group, PFS Progress-free survival

ISSN: 1465-542X